Hunan Cancer Hospital
🇨🇳China
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Drug: intensive treatmentDrug: Maintenance treatment
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05842525
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Phase 2
Recruiting
- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05633914
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05561686
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Phase 1
Recruiting
- Conditions
- Metastatic HER2 Negative Breast CarcinomaBrain MetastasesCapecitabineUDT1
- Interventions
- Drug: UTD1 combined with capecitabine
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05535413
- Locations
- 🇨🇳
Quchang Ouyang, Changsha, China
Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05460481
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05430906
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
Completed
- Conditions
- Metastatic Breast CancerGene AbnormalityCirculating Tumor DNA
- Interventions
- Drug: Case groupDrug: Control group
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 223
- Registration Number
- NCT05427617
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy
Completed
- Conditions
- HER2-positive Breast CancerBreast Neoplasms
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05367739
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
Recruiting
- Conditions
- Breast NeoplasmsNeoplastic Cells, CirculatingChemotherapy Effect
- Interventions
- Diagnostic Test: CTC detection
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05326295
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05206656
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath